Record mula sa primary source
Decision-gradeTopline na resulta
INBRX-106 + pembro ay mas mataas na ORR/CR/PFS kumpara sa pembro lamang sa 1L PD-L1 CPS≥20 HNSCC (HexAgon)
Ang randomisadong Phase 2 na data mula sa HexAgon study ay nagpapakita na ang INBRX-106 kasama ang pembrolizumab ay makabuluhang lumalampas sa pembrolizumab monotherapy sa maraming endpoint ng bisa sa first-line recurrent/metastatic HNSCC. Plano ng kumpanya na palawakin ang Phase 2 cohort sa HPV-positive na mga pasyente, na maaaring suportahan ang isang accelerated approval pathway sa pagtatapos ng 2028 o unang bahagi ng 2029.
Mahahalagang fact
- Na-file
- Set 28, 2026, 09:03 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
INBXInhibrx- Asset
- INBRX-106
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- ORR
- 80% kumpara sa 33%
- PFS
- NR kumpara sa 4.6 buwan
- PFS6
- 90% kumpara sa 33%
- CR rate
- 30% kumpara sa 0%
- pangkalahatang ORR
- 48.3% kumpara sa 26.5%
- pangkalahatang PFS
- 9.6 buwan kumpara sa 4.9 buwan
- pangkalahatang PFS6
- 72.4% kumpara sa 42.8%
- pangkalahatang CR rate
- 13.8% kumpara sa 0%
Sipi mula sa source
EX-99.1 2 inhibrxpresentation_sept.htm EX-99.1 inhibrxpresentation_sept INHIBRX Investor Presentation Innovation Driven Outcomes Focused • 2 Presentation disclaimer This presentation of Inhibrx Biosciences, Inc. (the “Company”) contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements regarding the Company’s business strategy, the Company’s plans to develop and commercialize its pro